Magnetic Ventures — Full Portfolio
22 tracked investments · listed companies and verified rows first
Amydis develops proprietary ocular tracers that detect molecular biomarkers for diseases of the eye, heart, and brain through non-invasive eye-based testing.
BiotechDigital HealthMedical DevicesLos Angeles, US
Stella Sarraf(Executive Officer, Director)James Khodabakhsh(Director)Mervyn Turner(Director)Faith Charles(Director)
Board seatChristine Aylward· per SEC Form D · $6M raise · filed Dec 2023
Miami Beach, US
Board seatChristine Aylward· per SEC Form D · $36.2M raise · filed Dec 2025
Co-investorsDCVC (Data Collective)
New Haven, US
Stephen Klapper(Executive Officer)Brandon Rice(Executive Officer)Aryeh Caroline(Executive Officer, Director)
BoardUmut Eser(Executive Officer)Joel Dudley(Director)in
Board seatChristine Aylward· per SEC Form D · $11.4M raise · filed Dec 2023
Co-investorsInnovation Endeavors
AppliedVR develops immersive therapeutic software using technology to deliver drug-free clinical treatments for patients.
Digital HealthHealthtechMedical DevicesLos Angeles, US
Matthew Stoudt(Co-Founder and CEO)inJosh Sackman(Co-Founder and President)in
BoardDavid Sackman(Chairman)
Co-investorsEntrada VenturesF-Prime CapitalJAZZ Venture PartnersPresence CapitalTechstars
Deep Genomics develops AI-based biological foundation models to identify drug targets and design molecules, aiming to speed up drug discovery.
AI & Machine LearningBiotechDeep TechToronto, CA
Brendan Frey(Chief Innovation Officer and Founder)Brian O'Callaghan(Chief Executive Officer)David Johnston(Chief Financial Officer)Clive Bertram(Chief Business Officer)Tom Masterson(Chief Operating Officer)Greg Hoffman(Chief Scientific Officer)
Co-investors11.2 CapitalFuture VenturesKensington Capital Partners LimitedSoftBank Vision FundTrue VenturesBloomberg Beta
Eclipsebio provides RNA biology analytical services and sequencing-based assays that help drug developers and researchers characterize RNA at nucleotide-level resolution and generate datasets for AI-driven drug discovery.
AI & Machine LearningBiotechDeep TechSan Diego, US
Eugene Yeo(Director)Peter Chu(Executive Officer, Director)Eric L Van Nostrand(Director)Hallie Kuhn(Director)
BoardEdmond Wong(Director)inDaniel Vasella(Director)
Co-investorsBrainstorm VenturesiGlobe PartnersPhoenix Venture Partners
AI-powered translational platform for developing novel molecules to treat psychiatric disease.
Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management.
AI & Machine LearningBiotechDigital HealthHealthtechNew York City, US
Jonathan Sporn(Founder)inAndrew Kruegel(Founder)inDalibor Sames(Founder)inJONATHAN SPORN(Founder)inAndrew Kruegel, Ph.D.(Executive Officer)Jonathan Sporn, M.D.(President and Chief Executive Officer)
Co-investorsAera VCFrontera Technology VenturesFrontier Path VCJames Beshara FundJLSNoetic+4 more
GroundGame.Health operates a technology platform and hyperlocal operating model that connects health plans, providers, employers, and community-based organizations to address barriers to care and social determinants of health.
Digital HealthHealthtechImpact & Social GoodSocialTampa, US
Susan Rawlings Molina(Executive Officer, Director, Promoter)inSridhar Akula(Executive Officer, Director)Aimee Dailey(Director)
BoardRobert Garber(Director)inShantanu Agrawal(Director)Jennifer Jarrell(Director)
Co-investors7wire VenturesCorewell Health VenturesRaptor Group
HiberCell develops therapeutic candidates targeting the Integrated Stress Response pathway to address treatment-resistant cancers, relapse, and metastasis.
BiotechMedical Devices
Julio Aguirre-Ghiso, Ph.D.(Co-Founder)
Co-investorsARCH Venture PartnersRaptor Group
Intelligent deep-tech clinical research platform for designing and executing impactful clinical trials.
Paradigm Health operates a platform that increases patient access to clinical trials through a provider-facing infrastructure combined with AI-powered research technology.
AI & Machine LearningHealthtechMedical DevicesSaaSColumbus, US
Kent Thoelke(Founder and Chief Executive Officer)inJonathan Hirsch(Chief Strategy and Growth Officer)
Co-investorsARCH Venture PartnersGeneral CatalystLux CapitalGV (Google Ventures)Mubadala Capital
Prompt is an Ambient AI product and research company that develops human-centered AI products designed to sense the physical environment.
AI & Machine LearningConsumerDeep TechSan Francisco, US
Tete Xiao(Founder)in
Co-investorsAbstract VenturesAIX VenturesDCVC (Data Collective)Neotribe VenturesBraidwellCDP Venture Capital+3 more
Proxima is a biotech company developing proximity therapeutics through a drug discovery engine and a structural proteomics data platform.
AI & Machine LearningBiotechDeep Tech
Jonathan Bernardini(Founder)in
Co-investorsModi VenturesDCVC (Data Collective)
Active-graph machine learning combined with single-cell analysis for advancing therapeutic candidates.
Relation is an end-to-end biotech company that combines single-cell multi-omics from patient tissue, functional assays, and machine learning to identify druggable targets and develop therapies for serious diseases.
AI & Machine LearningBiotechDeep Tech
Co-investorsDCVC (Data Collective)Hitachi VenturesRaptor GroupNVentures
Resilience is a contract development and manufacturing organization (CDMO) that manufactures complex pharmaceutical products and active pharmaceutical ingredients to broaden access to medicines and protect biopharmaceutical supply chains against disruption.
Advanced ManufacturingBiotechEnterprise SoftwareBlue Ash, US
William S. Marth(Chief Executive Officer)
BoardRobert Nelsen
Co-investors8VCARCH Venture PartnersCatalio Capital Management, LPGV (Google Ventures)Koch Disruptive TechnologiesLux Capital+4 more
Digital HealthHealthtechImpact & Social Good
Co-investors7wire VenturesCorewell Health VenturesRaptor Group
Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients.
BiotechHealthtechCambridge, US
Aaron Ring(Co-founder)Aashish Manglik(Co-founder)Jeff Landau(Chief Executive Officer)inRoland Gendron(Chief Business Officer)inMichelle Zhang(Chief Scientific Officer)in
BoardVineeta Agarwala(Director)in
Co-investorsRA CapitalAndreessen HorowitzOMX VenturesAxial VCGV (Google Ventures)LoLa Capital Partners+1 more
Transition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease.
AI & Machine LearningBiotechDeep TechCambridge, US
Tuomas Knowles(Executive Director, Co-Founder & Chief Technology Officer)Samuel Cohen(Executive Director & Co-Founder)G. Kelly Martin(Executive Chairman & Co-Founder)George Martin(Executive Officer, Director)Stephanie Torruella(Executive Officer)Preet Makkar(Executive Officer)
Co-investorsNorthpond VenturesLifeforce CapitalTaiho Ventures, LLCDolby Family Ventures
Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.
BiotechDigital HealthHealthtech
Vishal Patelin
Co-investorsAtlas VentureBorealis VenturesBorealis VenturesOrbiMedAscenta CapitalFidelity Investments+3 more
Weave Bio offers an AI-native regulatory platform for preparing and managing eCTD-formatted regulatory dossiers, automating data organization, authoring, review, publishing and response management across the therapeutic lifecycle.
AI & Machine LearningBiotechSaaSSan Francisco, US
Ari Caroline(Founder)
Co-investorsFirsthandVCGround Up VenturesRaptor GroupTMVUS Venture PartnersCharacter+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.